title: Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
abstract: BACKGROUND
  To evaluate the peripheral neuropathic changes induced by combination chemotherapy including paclitaxel (taxol), gemcitabine and cisplatin (TGC regimen).
  
  
  METHODS
  Eighteen patients with primary or recurrent ovarian cancer were treated with paclitaxel 150 or 110 mg/m2, respectively, together with gemcitabine 800 mg/m2 and cisplatin 75 mg/m2, 3 weekly for 6 cycles. Neurologic evaluation and quantitative assessment by vibration perception threshold (VPT) and grip strength took place before therapy, after 3 and 6 cycles of chemotherapy, and thereafter when possible.
  
  
  RESULTS
  Both neuropathic symptoms and signs developed in all patients (100%), becoming most prominent 3 months after the last course of chemotherapy. Grade 3 peripheral neuropathy developed in one patient during chemotherapy, and in 3 additional patients after cessation of therapy. No significant differences were observed between chemo-naive patients and pretreated patients.
  
  
  CONCLUSIONS
  This TGC combination is well tolerated in terms of peripheral neuropathy during therapy, although the off-therapy worsening caused by cisplatin remains a problem.
authors.affiliation: Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.
authors.forename: C C P
authors.initials: CC
authors.lastname: Verstappen
authors.forename: T J
authors.initials: TJ
authors.lastname: Postma
authors.forename: K
authors.initials: K
authors.lastname: Hoekman
authors.forename: J J
authors.initials: JJ
authors.lastname: Heimans
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009460:Neurologic Examination; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000175:diagnosis; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine